Commentary|Videos|June 3, 2026

ASCO 2026 Spotlights Unmet Needs Across Cancer Care

Author(s)Ella Hohmann, MS, Jeffrey Weinberg, MD , Alicia Morgans, MD, MPH

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.

At the 2026 annual meeting of the American Society of Clinical Oncology (ASCO), clinicians across oncology subspecialties converged on Chicago, Illinois, to assess progress and define the obstacles that still stand between patients and cures. Interview perspectives captured at the meeting revealed consistent themes, including a proliferation of treatment options outpacing the tools to select among them, persistent gaps in patient-clinician communication, and an ongoing struggle to translate laboratory promise into durable outcomes.

Related to this article

October 25th, 2026

AMCP Nexus 2026 to Address Key Shifts in Managed Care Pharmacy

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.

Adults with IgA nephropathy who received povetacicept had a 52.0% reduction in proteinuria at week 36 compared with 4.3% with placebo in the phase 3 RAINIER interim analysis. | Image credit: filins - stock.adpbe.com

October 24th, 2026

Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36

Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.

The KCC model raised optimal dialysis starts but cost Medicare $304.8 million in 2023. | Image credit: momius - stock.adobe.com

October 24th, 2026

Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care

At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.

In 2024, Medicare Advantage insurers denied 7.7% of nearly 53 million prior authorization requests, and 80.7% of the 11.5% of denials appealed were overturned. | Image Credit: Supatman - stock.adobe.com

October 23rd, 2026

Prior Authorizations, Trial Gaps Hinder Glomerular Disease Drug Access

Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.

Among 1332 patients in the US with genetically confirmed APOL1-mediated kidney disease, 45.7% had chronic kidney disease stage 4 or 5 at a mean age of 45.6 years. | Image credit: amazing studio - stock.adobe.com

October 22nd, 2026

Real-World AMKD Data Highlight Quick Progression, Unmet Needs

Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.

October 24th, 2026

One-Size Dialysis Volume Goals Fall Short in CKD: Jennifer Flythe, MD

Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.

A safety-net outpatient dialysis pathway for unfunded patients with ESKD cut monthly ED visits from 29.7 to 4.0 and lowered direct costs by 83%, data show. | Image credit: mailsonpignata - stock.adobe.com

October 24th, 2026

Dialysis Access, Church CKD Screening Address Kidney Care Inequities

Outpatient dialysis for unfunded patients with ESKD cut ED reliance and costs, while church-based CKD screening improved blood pressure.

Advocacy - Halfpoint - stock.adobe.com.jpeg

October 23rd, 2026

How ID, HIV Clinicians Can Influence Policy in an Election Year

At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.